Cardiac Steatosis in Diabetes Mellitus: A 1H-Magnetic Resonance Spectroscopy Study

Background— The risk of heart failure in type 2 diabetes mellitus is greater than can be accounted for by hypertension and coronary artery disease. Rodent studies indicate that in obesity and type 2 diabetes mellitus, lipid overstorage in cardiac myocytes produces lipotoxic intermediates that cause apoptosis, which leads to heart failure. In humans with diabetes mellitus, cardiac steatosis previously has been demonstrated in explanted hearts of patients with end-stage nonischemic cardiomyopathy. Whether cardiac steatosis precedes the onset of cardiomyopathy in individuals with impaired glucose tolerance or in patients with type 2 diabetes mellitus is unknown. Methods and Results— To represent the progressive stages in the natural history of type 2 diabetes mellitus, we stratified 134 individuals (age 45±12 years) into 1 of 4 groups: (1) lean normoglycemic (lean), (2) overweight and obese normoglycemic (obese), (3) impaired glucose tolerance, and (4) type 2 diabetes mellitus. Localized 1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging were used to quantify myocardial triglyceride content and left ventricular function, respectively. Compared with lean subjects, myocardial triglyceride content was 2.3-fold higher in those with impaired glucose tolerance and 2.1-fold higher in those with type 2 diabetes mellitus (P<0.05). Left ventricular ejection fraction was normal and comparable across all groups. Conclusions— In humans, impaired glucose tolerance is accompanied by cardiac steatosis, which precedes the onset of type 2 diabetes mellitus and left ventricular systolic dysfunction. Thus, lipid overstorage in human cardiac myocytes is an early manifestation in the pathogenesis of type 2 diabetes mellitus and is evident in the absence of heart failure.

[1]  J. Richardson,et al.  Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Grundy,et al.  Relationships of generalized and regional adiposity to insulin sensitivity in men. , 1995, The Journal of clinical investigation.

[3]  E. Gregg,et al.  Secular Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US Adults , 2005 .

[4]  P. Herrero,et al.  A novel mouse model of lipotoxic cardiomyopathy. , 2001, The Journal of clinical investigation.

[5]  K. Flegal,et al.  Prevalence of overweight and obesity in the United States, 1999-2004. , 2006, JAMA.

[6]  G. Metzger,et al.  Myocardial triglycerides and systolic function in humans: In vivo evaluation by localized proton spectroscopy and cardiac imaging , 2003, Magnetic resonance in medicine.

[7]  J. McGavock,et al.  Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. , 2005, American journal of physiology. Endocrinology and metabolism.

[8]  J. Mitchell,et al.  Left ventricular dimensions and mass using magnetic resonance imaging in female endurance athletes. , 1992, The American journal of cardiology.

[9]  G. Noon,et al.  Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  L. Orci,et al.  Lipotoxic heart disease in obese rats: implications for human obesity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Schaffer,et al.  Lipotoxicity: when tissues overeat , 2003, Current opinion in lipidology.

[12]  M. Carnethon.  Can we out-run the diabetes epidemic? , 2007, Diabetologia.

[13]  Ronald M Peshock,et al.  The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. , 2004, The American journal of cardiology.

[14]  A. Garg,et al.  Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. , 2003, Diabetes care.

[15]  D. Severson,et al.  Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. , 2002, American journal of physiology. Heart and circulatory physiology.

[16]  D. Pennell,et al.  Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major , 2005, Journal of magnetic resonance imaging : JMRI.

[17]  William C Stanley,et al.  Myocardial substrate metabolism in the normal and failing heart. , 2005, Physiological reviews.

[18]  J. Schaffer,et al.  Lipotoxicity: when tissues overeat , 2003, Current opinion in lipidology.

[19]  E. Abel,et al.  Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. , 2006, Physiology.

[20]  Dudley J Pennell,et al.  Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. , 2002, The American journal of cardiology.

[21]  James Ze Wang,et al.  Comparison of cine magnetic resonance imaging and Doppler echocardiography for evaluation of left ventricular diastolic function. , 1997, The American journal of cardiology.

[22]  E. Bollano,et al.  Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. , 2003, Endocrinology.

[23]  J. McGarry,et al.  Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. , 1998, Diabetes.

[24]  M. Takata,et al.  Ejection Fraction Revisited , 1991, Anesthesiology.

[25]  H. Taegtmeyer,et al.  Adaptation and Maladaptation of the Heart in Diabetes: Part II: Potential Mechanisms , 2002, Circulation.

[26]  M. Roden,et al.  Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. , 2002, Diabetes.

[27]  C. R. Wilson,et al.  The metabolic syndrome and the heart--a considered opinion. , 2006, Clinical research in cardiology : official journal of the German Cardiac Society.

[28]  R W Parkey,et al.  Estimation of human myocardial mass with MR imaging. , 1988, Radiology.

[29]  J. McGavock,et al.  Adiposity of the Heart*, Revisited , 2006, Annals of Internal Medicine.

[30]  B. Rodrigues,et al.  Metabolic disturbances in diabetic cardiomyopathy , 1998, Molecular and Cellular Biochemistry.

[31]  G. Lopaschuk,et al.  Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. , 2003, American journal of physiology. Endocrinology and metabolism.

[32]  Xianlin Han,et al.  Transgenic Expression of Fatty Acid Transport Protein 1 in the Heart Causes Lipotoxic Cardiomyopathy , 2005, Circulation research.

[33]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[34]  Thomas D. Giles,et al.  Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[35]  Ian Janssen,et al.  Vascular Risks and Management of Obesity in Children and Adolescents , 2006, Vascular health and risk management.

[36]  S. Grundy,et al.  Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. , 2005, American journal of physiology. Endocrinology and metabolism.

[37]  G. Lopaschuk,et al.  Energy Metabolism in the Hypertrophied Heart , 2002, Heart Failure Reviews.

[38]  Xianlin Han,et al.  A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Homma,et al.  Apolipoprotein B Production Reduces Lipotoxic Cardiomyopathy , 2004, Journal of Biological Chemistry.